Descripción de la empresa
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences entity dedicated to the development of anti-fibrotic and anti-inflammatory therapies designed for the treatment of heart diseases. The company functions within the Healthcare sector, specifically categorized under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized pharmaceutical solutions for specific therapeutic areas rather than broad generic distribution. As of the latest available data, the firm holds a market capitalization of $156.35M, while specific figures for annual revenue and employee count are not disclosed in the current financial dataset. These valuation metrics, combined with the absence of reported revenue data, indicate that the company is in a pre-revenue or early-stage commercialization phase typical of clinical-stage biotechnology firms, where value is derived primarily from intellectual property and pipeline progress rather than current sales volume or operational scale.
Salud financiera
The financial statements reveal a net income of $-33,818,872 and an EBITDA of $-34,214,312, while revenue figures for the trailing twelve months are not available in the provided records. The substantial negative gap between the non-disclosed revenue and the significant net loss highlights a cost structure dominated by research, development, and clinical trial expenses common in the drug manufacturing sector before commercialization begins. Free cash flow stands at $-23,727,256, indicating that the company is consuming cash reserves to fund its operations and pipeline development rather than generating surplus liquidity for shareholder distributions. All three reported margins—Gross Margin, Operating Margin, and Profit Margin—are listed at 0.0%, a metric that reflects the accounting treatment of a pre-revenue entity where no sales have been recognized to calculate these specific profitability ratios. Regarding liquidity and leverage, the company maintains cash assets of $21.42M against total debt of $125,523, resulting in a debt-to-equity ratio of 0.70. While the absolute debt figure is relatively low, the company's balance sheet is currently leveraged in the traditional sense due to the debt obligation, though the cash position provides a buffer. The current ratio is reported at 4.16, suggesting a strong short-term liquidity position with current assets significantly exceeding current liabilities. Return on Equity stands at -158.8% and Return on Assets at -77.3%, metrics that indicate management is currently utilizing shareholder capital and assets to generate losses rather than positive returns, which is characteristic of companies in heavy investment phases.
Evaluación de valoración
Valuation multiples for Cardiol Therapeutics Inc. include a trailing P/E ratio of N/A and a forward P/E of -8.23, the latter implying negative expected earnings that preclude a standard trailing earnings-based valuation. The price-to-book ratio is recorded at 17.86, indicating that the market values the company's equity at a significant premium relative to its book value, a phenomenon often driven by the high potential value of its clinical pipeline rather than tangible assets. Alternative valuation metrics such as the price-to-sales ratio, which is N/A due to lack of sales data, and an EV/EBITDA of -3.38, suggest that traditional multiple-based comparisons are not applicable or indicative for a firm without positive earnings or sales. The stock has exhibited a 52-week high of $1.59 and a 52-week low of $0.80; without the specific current trading price to calculate the exact percentage deviation, the valuation range reflects a trading band of $0.79 in width within which the security has fluctuated. The beta value is listed as N/A, meaning there is no calculated volatility metric available to assess the stock's sensitivity to broader market movements relative to the S&P 500.
Growth & Income
Growth metrics for the company show revenue growth (YoY) and earnings growth (YoY) as N/A, as the firm has not yet generated sufficient revenue to calculate year-over-year growth rates. Consequently, it is impossible to determine whether earnings are growing faster or slower than revenue, as both metrics are currently undefined in the financial data. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning no cash is distributed to shareholders and all available earnings are theoretically available for reinvestment, though currently lost to operational deficits. The overall growth and income profile is defined by a reliance on capital markets for funding operations rather than organic revenue expansion or dividend income, with the company's value proposition resting entirely on the potential future success of its lead product candidate, CardiolRx, in Phase III trials.